A5029862175- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Ovarian cancer diagnosis and treatment
- Phagocytosis and Immune Regulation
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Colorectal Cancer Screening and Detection
- PARP inhibition in cancer therapy
- Multiple Myeloma Research and Treatments
- Cancer Mechanisms and Therapy
- CAR-T cell therapy research
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Endometrial and Cervical Cancer Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Ferroptosis and cancer prognosis
- Central Venous Catheters and Hemodialysis
Whitehead Institute for Biomedical Research
2022-2024
Dana-Farber Cancer Institute
2020-2024
Harvard University
2020-2024
Brigham and Women's Hospital
2024
University of Massachusetts Boston
2023
Boston Medical Center
2018-2021
Boston University
2018-2021
University of Southern California
2016-2019
USC Norris Comprehensive Cancer Center
2016-2019
Hebrew University of Jerusalem
2015
Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, ongoing studies suggest they may be most effective when used combination with other anticancer agents. Here, we developed a novel screening platform identify drugs that render lung cancer cells more vulnerable macrophage attack, identified therapeutic synergy exists between...
Background Breast cancer (BC) is the most common and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 BRCA2 ( BRCA ) mutations explain less than one‐half hereditary BC, proportion associated with other BC genes unknown. Methods Germline DNA from 1054 ‐mutation–negative Hispanic women (BC diagnosed at age <51 years, bilateral breast ovarian cancer, or ages 51‐70 years ≥2 first‐degree second‐degree relatives who had <70 years), 312 local...
Identifying stage II patients with colorectal cancer (CRC) at higher risk of progression is a clinical priority in order to optimize the advantages adjuvant chemotherapy while avoiding unnecessary toxicity. Recently, intensity and quality host immune response tumor microenvironment have been reported an important role tumorigenesis inverse association progression. This well established microsatellite instable CRC. In this work, we aim assess usefulness measures T-cell infiltration as...
Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe landscape frameshift mutations (FSs) and evaluated their role as a predictive biomarker ICI in clinical cohort patients. Methods Comprehensive genomic profiling was performed on solid samples examining at least 324 genes. The included patients metastatic...
Objective Reduced diversity at Human Leukocyte Antigen (HLA) loci may adversely affect the host’s ability to recognize tumor neoantigens and subsequently increase disease burden. We hypothesized that increased heterozygosity HLA is associated with a reduced risk of developing colorectal cancer (CRC). Methods imputed class I II four-digit alleles using genotype data from population-based study 5,406 cases 4,635 controls Molecular Epidemiology Colorectal Cancer Study (MECC). Heterozygosity...
Introduction: Ovarian cancer is the leading cause of gynecologic death, owing to high rates incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian because their role initiation and progression cancers. Experience non-ovarian cancers suggests that STK inhibitors are active against tumors with specific molecular alterations.Areas covered: This review discusses development phase II/III clinical trials...
Pancreatic cystic lesions (PCLs) are a heterogenous group of with varying degrees malignant potential. PCLs often incidentally detected on imaging. Management for patients without an immediate indication resection or tissue sampling entails radiographic surveillance to assess features concerning transformation. This study aims determine the rates adherence recommendations incidental PCLs, and identify factors associated loss follow-up.We conducted single-centre retrospective at tertiary...
Overall survival (OS) in patients with multiple myeloma (MM) varies across racial and ethnic groups [1]. Prior to the early 2000s, black were shown have a advantage over white ...
Objective The immune response to invasive carcinoma has been the focus of published work, but little is known about adaptive bronchial premalignant lesions (PMLs), precursors lung squamous cell carcinoma. This study was designed characterize T receptor (TCR) repertoire in PMLs and its association with clinical, pathological, molecular features. Methods Endobronchial biopsies (n=295) brushings (n=137) from high-risk subjects (n=50), undergoing cancer screening at approximately 1-year...
Using the electronic health record to address underdiagnosis of Lynch syndrome
We present a case of 47-year-old man with severe thrombocytopenia. The differential diagnosis for thrombocytopenia is wide. assessment includes an evaluation falsely low platelet counts (pseudothrombocytopenia), immune-mediated destruction, bone marrow dysfunction, or increased consumption and sequestration. After extensive systematic workup, we found relationship his haemodialysis. Although not widely recognised by clinicians, partly due to incomplete understanding its pathophysiology,...
Abstract Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown ongoing studies suggest they may be most effective when used combination with other anticancer agents. Here, we developed a novel screening platform identify drugs that render lung cancer cells more vulnerable macrophage attack, identified therapeutic synergy exists between...